<DOC>
	<DOCNO>NCT01303692</DOCNO>
	<brief_summary>Comparison bone mineral loss prostate cancer patient receive GnRH agonist -plus anti-androgen agent</brief_summary>
	<brief_title>Comparison Bone Mineral Loss Prostate Cancer Patients Who Receiving GnRH Agonist -Plus Anti-androgen Agent</brief_title>
	<detailed_description>MC MD</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<criteria>Korean prostate cancer 50 year old pathological confirmation Patients receive GnRH antagonist GnRH agonist plus anti androgen combination within 6 month since start . Patients measure bone density level start receive hormone therapy . Patients treated antiosteoporosis drug treat bisphosphate due BMD T score 3.0 . Patients hard analyse attach bone disease . Patients hard analysed limitation chart record accord investigators'discretion .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>bone mineral loss</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>GnRH agonist alone vs. GnRH agonist plus anti-androgen combination</keyword>
</DOC>